Bicara Therapeutics Inc. (BCAX) fair value analysis
Nasdaq · Updated 2026-10-19
BCAX price how computed
Valuation status
No fair-value estimate yetBCAX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for BCAX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $16.78
- Sector
- Healthcare
- 12-month range
- $13.93–$30.40
- Market cap
- $1.11B
- From 52-week high
- -44.8%
- Shares outstanding
- 66.2M
- Rank in Healthcare by quality score
- #224 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops novel therapies focused on immuno-oncology and other therapeutic areas. The company is headquartered in the United States and operates as a publicly traded entity on the Nasdaq exchange.
BCAX currently ranks #224 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.11B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-3.10
- Debt / equity
- 0.00
- Shares outstanding
- 66.2M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 22 · oversold
- 50-day average
- $21.75
- 200-day average
- $21.30
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-09
- Last 8 quarters vs consensus
- 1 beat, 7 missed
- Quarter by quarter
- 2026-06 ▼ miss (-6.5%)
2026-03 ▼ miss (-43.1%)
2025-12 ▼ miss (-4.0%)
2025-09 ▼ miss (-26.4%)
2025-06 ▲ beat (+7.4%)
2025-03 ▼ miss (-70.0%)
2024-12 ▼ miss (-38.1%)
2024-09 ▼ miss (-220.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 13 buy · 1 hold · 0 sell (14 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $35.5
- Target vs last price
- +111.6%
What our data shows for BCAX
- Shares are trading in the lower third of their 12-month price range of $13.93–$30.40.
- The 14-day relative strength index sits at an oversold 22.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BCAX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the BCAX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BCAX stock undervalued?
TickrTrends has no fair-value estimate for BCAX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is BCAX's TickrTrends verdict?
BCAX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does BCAX compare to other Healthcare stocks?
BCAX ranks #224 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BCAX overbought or oversold?
BCAX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does BCAX report earnings next?
BCAX's next earnings report is scheduled for 2026-11-09, per the published earnings calendar.
Does BCAX usually beat earnings estimates?
Over its last 8 reported quarters BCAX beat the consensus estimate 1 times and missed 7 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BCAX?
Of 14 analysts covering BCAX, 13 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $35.5 (+111.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.